Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Photoreceptors and Visual Pathways

Photoreceptors and Visual Pathways

At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category, whereas...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ellipsoid Zone Reflectivity: Exploring its Potential as a Novel Non-Invasive Biomarker for Assessing Mitochondrial Function.

Neuro-ophthalmology (Aeolus Press)·2024

Same author

Pattern ERGs suggest a possible retinal contribution to the visual acuity loss in acute optic neuritis.

Documenta ophthalmologica. Advances in ophthalmology·2022

Same author

Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria.

Multiple sclerosis (Houndmills, Basingstoke, England)·2014

Same author

Diagnostic features of the autoimmune retinopathies.

Autoimmunity reviews·2014

Same author

Response to 'Comment on Adult Horner's syndrome: a combined clinical, pharmacological, and imaging algorithm'.

Eye (London, England)·2013

Same author

Patterns of non-embolic transient monocular visual field loss.

Journal of neurology·2013

Search research articles

Related Experiment Video

Updated: May 27, 2026

Vibratome Sectioning Mouse Retina to Prepare Photoreceptor Cultures

Vibratome Sectioning Mouse Retina to Prepare Photoreceptor Cultures

Published on: December 22, 2014

Understanding and interpreting vision safety issues with vigabatrin therapy.

G T Plant¹, R C Sergott

¹Department of Neuro-Ophthalmology, National Hospital for Neurology and Neurosurgery, London, UK. gordon@plant.globalnet.co.uk

Acta Neurologica Scandinavica. Supplementum

|November 9, 2011

Summary

Vigabatrin, used for epilepsy, can cause visual field defects. However, these defects also appear in some patients not taking vigabatrin, suggesting epilepsy itself may contribute to vision issues.

Related Experiment Videos

Last Updated: May 27, 2026

Vibratome Sectioning Mouse Retina to Prepare Photoreceptor Cultures

Vibratome Sectioning Mouse Retina to Prepare Photoreceptor Cultures

Published on: December 22, 2014

Area of Science:

Neuroscience
Ophthalmology

Background:

Vigabatrin is an anti-seizure medication effective for refractory complex partial seizures and infantile spasms.
Vigabatrin carries a risk of retinopathy, specifically peripheral visual field defects (pVFDs).
Monitoring visual function is crucial for patients on vigabatrin.

Purpose of the Study:

To investigate the association between pVFDs and epilepsy in patients not yet treated with vigabatrin.
To identify confounding factors influencing pVFD prevalence, such as other medications or assessment methods.
To better understand the prevalence of pVFDs directly linked to vigabatrin use.

Main Methods:

Prospective cohort study.
Analysis of case series and case reports.
Review of published data on vigabatrin-associated retinal toxicity and taurine.

Main Results:

Bilateral visual field constriction was observed in vigabatrin-naïve epilepsy patients, though less frequently than in vigabatrin users.
Other GABAergic antiepileptic therapies may also be associated with pVFDs.
Taurine deficiency is linked to vigabatrin retinopathy, with potential preventive roles for taurine.

Conclusions:

Peripheral visual field defects in epilepsy patients are not solely attributable to vigabatrin.
Epilepsy itself, and potentially other GABAergic treatments, may contribute to pVFDs.
Further research into taurine's role in preventing vigabatrin-induced retinopathy is warranted.